Preview

August 2020

In the next issue of Pharma Technology Focus, out in August, we round up some of the most significant developments to come out of Genomics England since its inception in 2013, and as countries around the world prepare to face the financial impact of Covid-19 lockdowns, we examine what pharma companies can learn from previous economic crises.

Also, we explore the real-world logistics of supplying Covid-19 treatments to patients around the world, speak to the team behind Innovative Trials to find out how participants are recruited and managd in clinical trials, and learn about a so-called ‘master key’ antibiotic, which is making waves for its potential in the fight against antimicrobial resistance.

Plus, we assess the current state of the autism treatment pipeline to find out why companies are abandoning potential drug candidates, explore the potential of crystal chemistry in drug development, and investigate the science behind the use of psychedelic mushrooms in mental health treatments. 

EDITORIAL

Editor | Eloise McLennan

Group Editor | Susanne Hauner

Commissioning Editor| Daniel Garrun

Writers | Allie Nawrat, Chloe Kent, Abi Millar, Natalie Healey, Steve Gens, Remco Munnik
Magazine Designer | Marzia Del Gaone

Graphic Designers | Filipe Costa, Anett Arc, Ashley McPherson, Tyrrell Lowe, Noemi Balint, Petra Konyi-Kiss, Maria Gimenez, Martina Labaiova
Lead Designer | John Hammond 
Digital Publishing Director | Duncan West

Advertising

Sales Manager | Nimai Amin

+44 (0) 207 936 6453

Marketing

For media partnership enquiries please contact: Susanne Hauner

Pharma Technology focus is powered by h5mag

read past issues of pharma technology focus HERE

Copyright 2020 NRi Digital, a trading division of Verdict Media Ltd. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.

Go to article: Home | Breaking the BarrierGo to article: In this issueGo to article: NSFGo to article: ContentsGo to article: AlmacGo to article: NewsGo to article: VEGA Company Insight Go to article: VEGA AustraliaGo to article: Covid-19 executive briefing by GlobalDataGo to article: Gilead’s remdesivir a candidate for US government stockpiling or bulk buying in Go to article: Covid-19’s impact on trial PROs, other endpoints can be addressed via data stratification, sensitivity analysisGo to article: ILC Dover Go to article: Vitamin D affects Covid-19 mortalityGo to article: Clinical trial disruption due to Covid-19 has begun to slowGo to article: Covid-19 boosts big bio/pharma drug sales but Regeneron may be falling shortGo to article: MimotopesGo to article: The pharma industry briefingGo to article: Charting the ups and downs of the World Health OrganizationGo to article: Road to RECOVERY: a deep dive into the world’s largest Covid-19 drug trialGo to article: Salvaging clinical trials in the time of Covid-19Go to article: Intellectual property in the time of Covid-19Go to article: Molnár-Institute Company InsightGo to article: Molnar-InstituteGo to article: A plight for sore eyes: the latest developments in seasonal allergy treatmentGo to article: How research groups are tackling the problem of biologic drug delivery Go to article: Breaking the blood-brain barrier: neurology’s greatest challengeGo to article: Timeline: charting the history of immunotherapy, cancer treatment's fourth pillarGo to article: Creating a sure data footing for AIGo to article: Koehler eClinicalGo to article: Deals in brief powered by GlobalDataGo to article: The key list powered by GlobalDataGo to article: Global markets and indices powered by GlobalDataGo to article: Macro-economic indicators (1 of 2) powered by GlobalDataGo to article: Macro-economic indicators (2 of 2) powered by GlobalDataGo to article: EventsGo to article: Next issue